# Dan Mendelson

> Dan Mendelson is a Series B investor at JP Morgan Chase backing Health Care and Medical. See 9 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [JP Morgan Chase](https://shizune.co/investors/profile/jpmorgan-chase-co)
- Location: Washington, United States
- Total investments: 9
- Last investment: Mar 2026
- Lead investor: 56%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/dan-mendelson-97541311/
- Website: https://x.com/dnmendelson

Dan Mendelson is a Series B investor at JP Morgan Chase in Washington focused on Health Care and Medical. Dan Mendelson is the CEO of Morgan Health at JPMorgan Chase & Co., a Board Member at Champions Oncology and Vera Whole Health, and an Adjunct Faculty at Georgetown University McDonough School of Business. He attended Harvard Kennedy School and Oberlin College.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 8 | 89% |
| Medical | 6 | 67% |
| Hospital | 2 | 22% |
| Wellness | 2 | 22% |
| Therapeutics | 2 | 22% |

14 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 22% |
| Funding Round | 2 | 22% |
| Series A | 1 | 11% |
| Series D | 1 | 11% |
| Private Equity | 1 | 11% |

7 stages tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Lantern | Lantern is a specialty care platform connecting people with health plan members for surgeries and cancer treatment. | $30M | Venture - Series Unknown | Mar 19, 2026 |  |
| Aradigm Health | Aradigm Health platform enables access to next generation of transformative therapies—cell and gene therapies (CGTs). | $20M | Series A | Dec 09, 2025 |  |
| Thyme Care | Thyme Care is a healthcare company that provides oncology care management services. The company offers a patient- and provider-integrated oncology solution, partnering with health plans to facilitate whole-person care for their members. Thyme Care seeks to revolutionize cancer care by providing personalized and holistic support to patients. Thecompany envisions a future where every cancer patient can access high-quality, individualized care that meets their unique needs and circumstances. | $97M | Series D | Sep 25, 2025 |  |
| Cortica | Cortica is a rapidly growing healthcare company pioneering a unique and effective approach to treating neurodevelopmental conditions including autism spectrum disorder, speech and language delays, sensory processing disorder and other conditions that impact brain development. Harnessing insights and technologies from emerging neuroscience, Corticabrings together clinical specialists from a range of disciplines to design and deliver comprehensive care to children with developmental differences. | $80M |  | Nov 20, 2024 |  |
| Kindbody | Kindbody operates a health and tech company intended to offer fertility services and treatments for the modern woman. It offers a full range of services including intrauterine insemination, in-vitro fertilization, donor support, egg freezing, and embryo freezing, enabling women to improve their overall health and wellbeing. | $25M |  | May 01, 2023 |  |
| Centivo | Centivo is a new type of health plan administrator that allows self-funded employers and clinicians to join forces and deliver high quality, affordable healthcare to their employees. An alternative to traditional insurance carriers or third-party administrators, Centivo offers the technology, network, claims processing, customer support, andpopulation health management to fully administer health benefits for all or a portion of an employee population.  The Centivo model emphasizes the partnership between individuals and their primary care team as the proper model to coordinate healthcare needs. Centivo’s clinical partners are dedicated to controlling costs and helping members navigate the healthcare system, aided by personalized patient/doctor matching tools. Members are rewarded for working with their primary care team and choosing high-value care and are supported through a user-friendly app and their concierge. Employers get an ally that diligently roots out waste and is accountable for performance.It was formed in 2017 and headquartered in New York, United States. | $30M | Series B | Jul 19, 2022 |  |
| Embold Health | Embold Health offers healthcare advocacy services that enhance decision-making through comprehensive data analysis. The company utilizes insights from insurers and government programs to provide users with valuable information about healthcare options. By integrating conversational AI technology, Embold Health assists individuals in identifyingsuitable healthcare providers, streamlining the process of finding care. The organization focuses on delivering performance data that helps users select physicians based on their specific healthcare needs. This approach aims to improve the overall quality of care while managing costs effectively. | $23M | Series B | Mar 16, 2022 |  |
| Vera Whole Health | Vera Whole Health specializes in primary care services. They design programs to help people achieve social, psychological, and physical well-being. Their primary care delivers patient-provider relationships through informatics, referral management, care coordination, and health coaching. | $50M | Private Equity | Aug 05, 2021 |  |
| Champions Oncology |  |  | Post-IPO Equity |  |  |

9 of 9 investments shown.

## Co-investors
- [Andreessen Horowitz](https://shizune.co/investors/profile/andreessen-horowitz) — VC Fund, 3 deals together
- [Autism Impact Fund](https://shizune.co/investors/profile/autism-impact-fund) — VC Fund, 2 deals together
- [CVS Health Ventures](https://shizune.co/investors/profile/cvs-health-ventures) — VC Fund, 2 deals together
- [Echo Health Ventures](https://shizune.co/investors/profile/echo-health-ventures-llc) — VC Fund, 2 deals together
- [Frist Cressey Ventures](https://shizune.co/investors/profile/frist-cresseyventures) — VC Fund, 2 deals together
- [Parkway Venture Capital](https://shizune.co/investors/profile/parkway-venture-capital) — VC Fund, 2 deals together

## About JP Morgan Chase

VC Fund · New York, United States

JPMorgan Chase is a financial holding company, provides various financial services worldwide. The company's Investment Bank segment provides investment banking products and services, including advising on corporate strategy and structure, capital raising in equity and debt markets, risk management, market-making in cash securities andderivative instruments, and prime brokerage and research.It was founded in February 2000 and is based in New York, United States.

5 contacts available at JP Morgan Chase.

| Name | Title | Profile |
| --- | --- | --- |
| Dan Mendelson | CEO of Morgan Health | https://shizune.co/investors/profile/dan-mendelson |
| Douglas B. Petno | Commercial Banking CEO | https://shizune.co/investors/profile/douglas-b-petno |
| Lori Beer | Global Chief Information Officer | https://shizune.co/investors/profile/lori-beer |
| Adah Ojile | Executive Director | https://shizune.co/investors/profile/adah-ojile |
| Barbara Alcaraz Silva | Industry Executive | https://shizune.co/investors/profile/barbara-alcaraz-silva |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Dan Mendelson invest in?

Dan Mendelson invests primarily in Health Care, Medical and Hospital startups, most often at Series B and Funding Round stage. Most of the 9 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Dan Mendelson last invest?

The most recent investment recorded for Dan Mendelson closed in Mar 2026. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co